Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 15/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979881 | 1.00 | RPS6KA2 (0.59) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL19252943 | 0.84 | RPS6KA2 (0.53) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4040510 | 0.84 | RPS6KA2 (0.53) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4038900 | 0.84 | RPS6KA2 (0.52) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4040515 | 0.84 | RPS6KA2 (0.53) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL19252944 | 0.84 | RPS6KA2 (0.53) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4038902 | 0.84 | RPS6KA2 (0.52) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4044891 | 0.82 | HRH3 (0.56) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL4041103 | 0.82 | HRH3 (0.56) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 | |
| SCHEMBL2983427 | 0.81 | HRH3 (0.55) | RPS6KA2RPS6KA3HRH3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | RPS6KA2 1016/4885RPS6KA3 1180/4885HRH3 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.